Off-Label Promotion Risk in Media Targeting and Copy
How pharma media can create off-label promotion risk through targeting, keywords, imagery, and placements, and the controls media teams use to stay on label.
The short answer
Off-label promotion means promoting a drug for a use, population, or dose not in its approved labeling. In media, risk comes not only from copy but from targeting HCP specialties or patient audiences that mostly treat unapproved uses, buying search keywords for unapproved conditions, using imagery that suggests other populations, and placing ads in content about other conditions. Controls include label-based targeting rules, keyword reviews, and documenting the rationale for each audience.
Teams usually think of off-label risk as a copy problem. Reviewers check the words. But media choices also communicate. An ad that says nothing off-label can still suggest an unapproved use through where it runs and who it is shown to.
How media creates risk
| Media choice | How it can suggest an unapproved use |
|---|---|
| HCP specialty targeting | Targeting a specialty that mainly treats unapproved conditions |
| Patient audiences | Segments defined by a condition outside the label |
| Search keywords | Bidding on unapproved conditions or doses |
| Contextual placement | Running in content about a different condition |
| Imagery | Showing people outside the approved population |
| Retargeting | Following users from pages about unapproved uses |
Controls
Label-based targeting rules
Write down which specialties, conditions, and audiences align with the approved indication. Require a rationale for any audience outside the core.
Specialty review
Specialties are not always clean. The HCP specialty ambiguity article explains how to build confidence tiers. Avoid adding specialties just to increase scale.
Keyword governance
- Review keyword lists against the label.
- Add negative keywords for unapproved conditions and populations.
- Review search query reports regularly for drift.
See pharmaceutical PPC.
Contextual and placement controls
Exclude content categories about unrelated conditions. Review placement reports.
Creative review for imagery
Check that people shown fit the approved population.
Documentation
For each campaign, keep:
- The audience definitions and rationale.
- Keyword lists and negatives.
- Contextual categories included and excluded.
- Review approvals.
Documentation shows that targeting choices were deliberate and on label.
Common mistakes
- Adding specialties to reach impression goals.
- Broad-match keywords without negative lists.
- Lookalike audiences that drift toward unapproved uses.
- Assuming targeting is not reviewed by anyone.
A targeting review worksheet
Add this worksheet to review submissions for any campaign with targeting choices.
| Targeting element | Value | Rationale tied to label | Reviewer note |
|---|---|---|---|
| HCP specialties included | Rheumatology, dermatology | Approved indications treated by these specialties | |
| Specialties excluded | Gastroenterology | Treats conditions outside label | |
| Patient audience definition | Adults interested in plaque psoriasis | Matches approved indication and population | |
| Contextual categories | Psoriasis, skin health | On-label condition | |
| Contextual exclusions | Other inflammatory conditions | Unapproved uses | |
| Keyword themes | Brand, psoriasis treatment | On label | |
| Negative keywords | Unapproved conditions, off-label dosing terms | Prevents off-label queries | |
| Lookalike or modeled audiences | Seed and drift checks | Ensure model stays on label |
Hypothetical values for illustration.
Monitoring after launch
- Review search query reports weekly for off-label terms.
- Review placement and content reports monthly.
- Check modeled audiences for drift, such as growing shares of specialties outside the plan.
- Log changes and send material changes back through review.
Off-label risk in media is often gradual: a keyword expansion here, an added specialty there. Regular monitoring catches it before it becomes a pattern.
Practical takeaway
Add targeting to your review submission: audience definitions, specialty lists, and keyword lists, with a one-line rationale tied to the label. Reviewers who see the targeting can catch risks that copy review alone will miss.
Frequently asked questions
Can targeting alone create off-label risk?
It can contribute. If an audience is chosen mainly because it treats a condition outside the label, the targeting may suggest promotion for that use. Document why each audience fits the approved indication.
Can pharma brands bid on keywords for unapproved uses?
Generally this is high risk. Keyword lists should be reviewed against the label, with negative keywords for unapproved conditions.
What about HCPs who treat both approved and unapproved uses?
Many do. The question is whether the targeting rationale and content stay focused on the approved indication.
Sources
- FDA, Office of Prescription Drug Promotion (OPDP)
- eCFR, 21 CFR 202.1 Prescription-drug advertisements
- FDA, Untitled Letters
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.